This article, by Cambridge Press (2025) is a narrative review, meaning it reviews and analyzes other papers already published; it argues that inconsistent findings in the menopause–brain health literature stem from oversimplification. Both menopause and menopause hormone therapy (MHT) are often treated as uniform, when in reality they are biologically diverse. The authors conducted a narrative review of human and preclinical studies to evaluate how differences in menopause type and hormone therapy influence cognitive aging and neurodegenerative risk.

Menopause as a neurological transition

The review positions menopause as a significant neurobiological event rather than purely a reproductive milestone. Declining ovarian hormones, particularly estradiol, are associated with changes in synaptic plasticity, brain metabolism, and neurogenesis. These shifts help explain observed changes in cognition and the increased risk of neurodegenerative diseases such as Alzheimer’s disease in postmenopausal women. Importantly, these effects are not uniform and depend on how menopause occurs.

Why menopause type matters

A key contribution of the article is its emphasis on menopause heterogeneity. Natural menopause, early or premature menopause, surgical menopause, and medically induced menopause differ in both timing and the rate of hormonal decline. Earlier onset and more abrupt hormone loss, particularly in surgical or induced menopause, are associated with poorer cognitive outcomes and increased neurological risk. The authors suggest that both the timing and speed of estrogen withdrawal are critical determinants of brain response.

Symptoms as indicators of brain impact

The review highlights that vasomotor symptoms, including hot flashes and night sweats, are not simply quality-of-life issues but are linked to underlying brain changes. These symptoms are associated with altered brain connectivity, sleep disruption, and measurable differences in cognitive performance, suggesting they may act as markers of neurological vulnerability during the menopausal transition.

Hormone therapy is not one intervention

A central argument of the paper is that MHT should not be treated as a single, uniform treatment. Differences in formulation, route of administration, dose, and timing all influence outcomes. Estradiol and estrone have distinct effects at the receptor level, while transdermal delivery may provide more stable and physiologically relevant hormone exposure compared to oral administration. These differences help explain why studies report conflicting effects of MHT on cognition and dementia risk.

Timing and the “critical window”

The authors discuss the critical window hypothesis, which proposes that initiating MHT closer to the onset of menopause may provide neuroprotective benefits, whereas later initiation may be less effective or potentially harmful. This is thought to reflect changes in the brain’s responsiveness to estrogen over time, adding another layer of complexity to clinical decision-making.

Individual variability and precision medicine

The review emphasizes that individual factors significantly modify outcomes. Genetic variation, particularly the presence of the apolipoprotein E epsilon 4 allele, influences Alzheimer’s disease risk and may alter response to hormone therapy. Reproductive history, health status, and lifestyle factors also contribute, supporting a move toward more personalized, precision-based approaches to menopause care.

Domain-specific cognitive effects

Cognitive changes associated with menopause and MHT are not global. Different domains, such as episodic memory, executive function, and attention, may be affected in distinct ways depending on menopause type and therapy characteristics. This domain specificity further contributes to variability across studies.

Conclusion

The review concludes that menopause and its treatment must be understood within a stratified framework that accounts for menopause type, symptom profile, hormone therapy formulation and delivery, timing, and individual biology. The authors argue that moving toward personalized approaches is essential to accurately understand and optimize brain health outcomes in women.

You can full the view study, here: https://www.cambridge.org/core/journals/the-britis...